Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer.
about
Subcutaneous Trastuzumab for HER2-positive Breast Cancer - Evidence and Practical Experience in 7 German CentersA randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjectsA randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01).Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study.Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration.Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia.Tolerability of High-Volume Subcutaneous Injections of a Viscous Placebo Buffer: A Randomized, Crossover Study in Healthy Subjects.Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous "manual syringe" injection or intravenously in women with HER2-positive early breast cancer.Pharmacokinetic Bioequivalence, Safety, and Immunogenicity of DMB-3111, a Trastuzumab Biosimilar, and Trastuzumab in Healthy Japanese Adult Males: Results of a Randomized Trial.Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer.The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectivesEvaluating the administration costs of biologic drugs: development of a cost algorithm.Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase.Use of a population pharmacokinetic approach for the clinical development of a fixed-dose subcutaneous formulation of trastuzumab.Evaluation of Left Ventricular Ejection Fractions in Breast Cancer Patients Undergoing Long-Term Trastuzumab Treatment.Therapeutic targeting of hyaluronan in the tumor stroma.Subcutaneous trastuzumab: a review of its use in HER2-positive breast cancer.Subcutaneous trastuzumab: drug development and current position.Role of subcutaneous formulation of trastuzumab in the treatment of patients with HER2-positive breast cancer.Molecular basis of high viscosity in concentrated antibody solutions: Strategies for high concentration drug product developmentTrastuzumab in the Treatment of Breast Cancer.Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins.A phase I dose-escalation and bioequivalence study of a trastuzumab biosimilar in healthy male volunteers.Subcutaneous Administration of Monoclonal Antibodies in Oncology.Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy males.Subcutaneous herceptin therapy.Potential Influence of Endothelial Adsorption on the Delayed Time to Maximum Concentration of Biopharmaceuticals.Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins.Measuring tissue back-pressure--in vivo injection forces during subcutaneous injection.Population PBPK modelling of trastuzumab: a framework for quantifying and predicting inter-individual variability.
P2860
Q28083633-38DE42B1-95AE-4B26-9A48-AAE382A6CD03Q33599885-33A0C804-6F5A-41E2-BB62-909F4B7373E3Q34635509-DCAEF3A4-C66C-49E9-BDCE-008D0EEDF52BQ35914396-78A12333-4E8E-44B6-A24B-4E6B12329965Q35967897-4F5CE7CC-4FCA-4C6D-8D99-60527F51EEEAQ36243612-2619D6C5-077F-4A0E-9EE6-E46884EC62E6Q36360553-E7EF6C1A-BD32-4FC5-9160-B7D825E2F4A1Q36445944-D9227BB7-E2D5-4950-9042-1D441944074BQ36558836-01F6F4D8-41EF-4BB4-92E4-2D2B8F7DDD2EQ36617983-F3465209-5387-48AB-9BD4-B6B63BFDC22AQ36677415-167F812A-0EF9-496A-B51B-77F1CA25245BQ36944368-F28D41C5-A8C9-495E-8040-A938AE37CB7CQ37182157-C68D9627-B473-4BA0-8950-3333579CFF2BQ37541753-FFA1617B-9849-4C93-A409-D42ECB707A73Q37543832-E2D36C74-0C8D-46C6-91F1-B7F4610D1C40Q38161392-DE23C400-A112-4053-A1C0-E2B8DAB2FA38Q38198973-A48C3D5D-DD35-4D8A-8DDA-77B503CE532FQ38207920-35DE579A-E3BB-4A00-807B-8956B21EFA36Q38257642-65213BAD-E5FE-4F80-BC43-CCE0D7C2CA44Q38688235-2932C566-CE0B-452A-AB6B-64B7D816FAF4Q38739914-D2B1710B-04FD-4554-95BF-067A76B48904Q38831148-80A90996-669C-4DDB-8C90-7B94460D4D42Q40183869-531713BC-9D63-4F78-86ED-BB2216915E8AQ42065760-551D934F-5A02-48FD-9F3B-9BEEF2DB1028Q45762090-8894EF44-F9ED-4490-8B0A-4A6A9F041308Q46952263-AC8A551C-D966-4570-A74F-D595D7975114Q49468322-FD9EA248-58F1-4376-B2B8-213C911A3A21Q50034109-0BA5A0D9-89B8-4811-BE97-F17E01A84D51Q53354258-352CFD2C-EE1D-4105-8CC8-8122D2C9C608Q53463994-C04BBE45-A6BE-4BB3-B5B2-59A1DC0B3015
P2860
Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Comparison of subcutaneous and ...... h HER2-positive breast cancer.
@en
Comparison of subcutaneous and ...... h HER2-positive breast cancer.
@nl
type
label
Comparison of subcutaneous and ...... h HER2-positive breast cancer.
@en
Comparison of subcutaneous and ...... h HER2-positive breast cancer.
@nl
prefLabel
Comparison of subcutaneous and ...... h HER2-positive breast cancer.
@en
Comparison of subcutaneous and ...... h HER2-positive breast cancer.
@nl
P2093
P2860
P356
P1476
Comparison of subcutaneous and ...... h HER2-positive breast cancer.
@en
P2093
Beate Bittner
Chris Wynne
Christian Schwabe
Christine McIntyre
Devonie Waaka
Vernon Harvey
P2860
P304
P356
10.1177/0091270012436560
P577
2013-02-01T00:00:00Z